Name | 2-[[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid |
---|---|
Synonyms | gsk360a |
Description | GSK360A is a potent and orally active HIF-PHD inhibitor with IC50 values of 10, 100, and 126 nM for PHD1, PHD2, and PHD3, respectively. GSK360A activates the HIF-1 alpha pathway and protect the failing heart after myocardial infarction (MI) [1]. |
---|---|
Related Catalog | |
In Vivo | GSK360A (30 mg/kg i.g.) 在已建立的心室功能障碍模型中改善长期心室功能、重塑和血管分布[1]。 Animal Model: male Lewis rats with ventricular dysfunction model[1] Dosage: 30 mg/kg Administration: oral gavage Result: Increased circulating levels of erythropoietin and hemoglobin and hemoxygenase-1 expression in the heart and skeletal muscle of male rats. |
References |
Molecular Formula | C17H17FN2O5 |
---|---|
Molecular Weight | 348.33 |
Exact Mass | 348.11200 |
PSA | 112.12000 |
LogP | 2.03550 |